Table 3.
Reduction of imiquimod therapy.
| No. (%) | Reduction (−) | Reduction (+) | Time to reductiona | p-Value | |
|---|---|---|---|---|---|
| Reduction of initial schedule | |||||
| Total | N = 63 | 53 (84.2%) | 10 (15.8%) | < 0.001 | |
| 1–2/week | 9 (14.3%) | 9 (100%) | 0 (0%) | ||
| 3–4/week | 43 (68.3%) | 42 (97.7%) | 1 (2.3%) | ||
| 5–7/week | 11 (17.4%) | 2 (18.2%) | 9 (81.8%) | ||
| Post-reduction schedule | |||||
| 1–2 → 1–2/week | 9 (14.3%) | ||||
| 3–4 → 3–4/week | 42 (67.7%) | ||||
| 3–4 → 1–2/week | 1 (1.6%) | ||||
| 5–7 → 5–7/week | 2 (3.2%) | ||||
| 5–7 → 3–4/week | 8 (12.7%) | ||||
| 5–7 → 1–2/week | 1 (1.6%) | ||||
| Reason for reductionb | n = 10 | ||||
| Irritation | 4 (40%) | 3 (1–5) | |||
| Erosion | 4 (40%) | 3.5 (1–5) | |||
| Pain | 2 (20%) | 4.5 (2–7) | |||
| Ulceration | 1 (10%) | 7 | |||
| Scheduled reduction | 3 (30%) | 3 | |||
| Not specified | 1 (10%) | 8 | |||
Chi-square test for p-value.
a
Median (range).
b
Total number exceeds 10 due to cases with multiple adverse reactions to imiquimod.